Health
Loma Linda University Health announces study of combination monoclonal antibody treatment for early COVID-19 – Loma Linda University Health
ACTIV-2 is studying multiple early COVID-19 treatments
Loma Linda University Health today announced the phase 2 study of the combination of the two monoclonal antibodies BRII-196 and BRII-198 for the treatment of non-hospitalized individuals with early COVID-19.Loma Linda University Health today announced the phase 2 study of the combination of the two monoclonal antibodies BRII-196 and BRII-198 for the treatment of non-hospitalized individuals with early COVID-19. This study is part of the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies…
-
Noosa News6 hours agoBrisbane man Benjamin Holt speaks out about teen who allegedly organised Airbnb party that led to his house being trashed
-
General23 hours agoTrump’s tariffs: a bad idea executed badly
-
Business4 hours agoSoaring one day, plunging the next. Why is the ASX 200 on a rollercoaster?
-
Business10 hours agoHow I’d build a $100,000 ASX portfolio from scratch